221 related articles for article (PubMed ID: 20200357)
1. Palmitoylation of oncogenic NRAS is essential for leukemogenesis.
Cuiffo B; Ren R
Blood; 2010 Apr; 115(17):3598-605. PubMed ID: 20200357
[TBL] [Abstract][Full Text] [Related]
2. Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A.
Zhao H; Liu P; Zhang R; Wu M; Li D; Zhao X; Zhang C; Jiao B; Chen B; Chen Z; Ren R
J Hematol Oncol; 2015 Dec; 8():132. PubMed ID: 26715448
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
Parikh C; Subrahmanyam R; Ren R
Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213
[TBL] [Abstract][Full Text] [Related]
4. N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation.
Wu M; Huang J; Zhang J; Benes C; Jiao B; Ren R
Mol Cancer Ther; 2017 Jan; 16(1):57-67. PubMed ID: 27760835
[TBL] [Abstract][Full Text] [Related]
5. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Tyner JW; Erickson H; Deininger MW; Willis SG; Eide CA; Levine RL; Heinrich MC; Gattermann N; Gilliland DG; Druker BJ; Loriaux MM
Blood; 2009 Feb; 113(8):1749-55. PubMed ID: 19075190
[TBL] [Abstract][Full Text] [Related]
6. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
7. RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia.
Ren JG; Xing B; Lv K; O'Keefe RA; Wu M; Wang R; Bauer KM; Ghazaryan A; Burslem GM; Zhang J; O'Connell RM; Pillai V; Hexner EO; Philips MR; Tong W
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317963
[TBL] [Abstract][Full Text] [Related]
8. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
Zambetti NA; Firestone AJ; Remsberg JR; Huang BJ; Wong JC; Long AM; Predovic M; Suciu RM; Inguva A; Kogan SC; Haigis KM; Cravatt BF; Shannon K
Blood; 2020 May; 135(20):1772-1782. PubMed ID: 32219446
[TBL] [Abstract][Full Text] [Related]
9. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
10. Mouse model for NRAS-induced leukemogenesis.
Parikh C; Ren R
Methods Enzymol; 2008; 439():15-24. PubMed ID: 18374153
[TBL] [Abstract][Full Text] [Related]
11. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
Kim WI; Matise I; Diers MD; Largaespada DA
Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
Xu J; Hedberg C; Dekker FJ; Li Q; Haigis KM; Hwang E; Waldmann H; Shannon K
Blood; 2012 Jan; 119(4):1032-5. PubMed ID: 22144181
[TBL] [Abstract][Full Text] [Related]
13. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
[TBL] [Abstract][Full Text] [Related]
14. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms for regulation of RAS palmitoylation and plasma membrane trafficking in hematopoietic malignancies.
Yu F; Qian Z
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317974
[TBL] [Abstract][Full Text] [Related]
16. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras.
Kalra R; Paderanga DC; Olson K; Shannon KM
Blood; 1994 Nov; 84(10):3435-9. PubMed ID: 7949098
[TBL] [Abstract][Full Text] [Related]
17. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
18. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
[TBL] [Abstract][Full Text] [Related]
19. Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling.
Song SP; Hennig A; Schubert K; Markwart R; Schmidt P; Prior IA; Böhmer FD; Rubio I
Biochem J; 2013 Sep; 454(2):323-32. PubMed ID: 23758196
[TBL] [Abstract][Full Text] [Related]
20. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
Wolf S; Rudolph C; Morgan M; Büsche G; Salguero G; Stripecke R; Schlegelberger B; Baum C; Modlich U
Oncogene; 2013 Jun; 32(25):3028-38. PubMed ID: 22847614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
